1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- Mucosta Superior to Hyaluronate in Improving Conjunctival Damage: Otsuka
May 23, 2011
- Operating Profits Down 60% for Ethical Drugs Wholesale Business: Medipal HD
May 23, 2011
- Dabigatran Superior to Warfarin Regardless of Stroke Risk: BI
May 23, 2011
- Alfresa HD: Double-digit Decline in Profits Despite Higher Sales
May 23, 2011
- Tofacitinib for RA Meets Primary Endpoints in PIII: Pfizer
May 23, 2011
- Operating Profits Down 60% Due to Stalled Price Negotiations: Suzuken
May 23, 2011
- Fingolimod Reduced Risk of MS Disability Progression: Novartis
May 23, 2011
- Operating Profits Drop 46.6% Due to Tough Price Negotiations: Toho HD
May 23, 2011
- T-DM1 Significantly Extends PFS in HER2-Positive Metastatic Breast Cancer: Roche
May 23, 2011
- DSP's Development Policy to Focus on Specialty Areas in the US
May 23, 2011
- Results of Dabigatran Sub-Analysis Similar in Japanese Patients vs Overall Study Population
May 23, 2011
- First European Launch of Rivalo in Spain: Kowa
May 23, 2011
- 7 Diseases to Gain Importance in Next 10 Years: JHSF Report
May 23, 2011
- Iberica HD to Expand Clinical Pharmacology Facilities in the US
May 23, 2011
- NBI Stresses Good Cost-effectiveness of Prazaxa
May 23, 2011
- Fuji Yakuhin: Drugstore Division Sales Up 1.4% in FY2010
May 23, 2011
- New Data Confirms Levemir's Efficacy for Type 1 Diabetes in Children Aged 2-5: Novo Nordisk
May 23, 2011
- Takeda Aims for Recovery through Shift toward New Products
May 23, 2011
- Prescriptions Filled by Growell HD Up 40%
May 23, 2011
- 39% of Hospitals Return to Black
May 23, 2011
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…